Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.6624
-0.0212 (-3.10%)
At close: Jun 13, 2025, 4:00 PM
0.6624
0.00 (0.00%)
Pre-market: Jun 16, 2025, 5:31 AM EDT

Xilio Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-54.3-58.24-76.4-88.22-75.8-55.22
Upgrade
Depreciation & Amortization
1.71.641.91.851.51.07
Upgrade
Loss (Gain) From Sale of Assets
00000.02-
Upgrade
Stock-Based Compensation
6.146.437.388.424.961.3
Upgrade
Other Operating Activities
--0.160.220.380.17
Upgrade
Change in Accounts Payable
1.241.53-2.060.49-2.822.93
Upgrade
Change in Unearned Revenue
39.8732.78----
Upgrade
Change in Other Net Operating Assets
26.46-2.520.411.52-8.9913.68
Upgrade
Operating Cash Flow
21.1-18.38-68.62-75.72-80.75-36.09
Upgrade
Capital Expenditures
-0.06-0.04-0.49-1.87-1.1-2.19
Upgrade
Investing Cash Flow
-0.06-0.04-0.49-1.87-1.1-2.19
Upgrade
Long-Term Debt Issued
----0.98-
Upgrade
Long-Term Debt Repaid
--3.38-6.75-0.09-1.09-0.1
Upgrade
Net Debt Issued (Repaid)
-0.03-3.38-6.75-0.09-0.11-0.1
Upgrade
Issuance of Common Stock
33.132.580.20.02116.640.16
Upgrade
Other Financing Activities
-----0.75-0.03
Upgrade
Financing Cash Flow
33.0729.2-6.55-0.07260.6710.03
Upgrade
Net Cash Flow
54.1210.78-75.66-77.66178.82-28.25
Upgrade
Free Cash Flow
21.04-18.41-69.11-77.59-81.85-38.28
Upgrade
Free Cash Flow Margin
226.91%-290.26%----
Upgrade
Free Cash Flow Per Share
0.32-0.34-2.51-2.83-14.60-73.08
Upgrade
Cash Interest Paid
-0.060.570.560.490.54
Upgrade
Levered Free Cash Flow
19.13-16.29-42.32-45.9-52.31-19.43
Upgrade
Unlevered Free Cash Flow
19.19-16.23-41.88-45.4-51.94-19.05
Upgrade
Change in Net Working Capital
-47.02-13.011.22-1.9110.39-14.88
Upgrade
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q